Secondary Skin Cancer in a Case with Long-term Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Noriaki Kawano¹, Shunou Nakamura², Kousuke Mochida³, Shuro Yoshida¹, Takuro Kuriyama¹, Takashi Nakaike¹, Tomonori Shimokawa¹, Taro Tochigi¹, Kiyoshi Yamashita¹, Koichi Mashiba¹, Ikuo Kikuchi¹, Aina Takarabe³, Sayaka Moriguchi⁴, Yasuo Mori¹, Katsuto Takenaka⁵, Kazuya Shimoda¹, Hidenobu Ochiai⁸ and Masahiro Amano²

Abstract:
Secondary malignancies that develop after allogeneic-hematopoietic stem cell transplantation (allo-HSCT) have become serious issues. A 47-year-old man who developed acute myeloid leukemia in 2009 and subsequently underwent allo-HSCT twice: in 2009 and 2011. In 2015, voriconazole for lung aspergillus was started. In 2018, chronic graft-versus-host disease (GVHD) and multiple actinic keratoses manifested at his head. In 2020, some lesions were diagnosed as squamous cell carcinoma, so voriconazole was withdrawn, and subsequent surgery and radiation led to remission. Long-term administration of voriconazole in addition to allo-HSCT and chronic GVHD may be closely related to secondary skin cancer.

Key words: secondary skin cancer, allo-HSCT, voriconazole, chronic GVHD

(Intern Med 61: 2771-2774, 2022)
(DOI: 10.2169/internalmedicine.8618-21)

Introduction

Allogeneic-hematopoietic stem cell transplantation (allo-HSCT) is performed for chemotherapy-resistant/refractory hematological malignancies in patients with a preserved organ function provided an acceptable donor is available (1). In recent years, the onset of secondary malignancies has become a serious issue with the increase in numbers of long-term survivors after allo-HSCT (2-9).

The clinical characteristics of secondary malignancy can be divided into three categories (2). Post-transplant lymphoproliferative disease (PTLD) usually occurs within a peak of two to three months after allo-HSCT (2), treatment-related myelodysplastic syndrome (MDS)/acute myeloid leu-kemia (AML) develops with a peak of two to three years after allo-HSCT (2), and solid tumors begin to develop at one year after allo-HSCT (2). In Japan, Atsuta et al. identified the onset of secondary malignancy in 269 cases among 17545 allo-HSCT patients from 1997 to 2007 in a Japanese data center for allo-HSCT (2). These authors also reported that the frequency was 0.7% at 5 years after allo-HSCT and 2.4% at 10 years after allo-HSCT (2).

Regarding the position of solid tumors, oral tumors, esophageal/colon tumors, and skin tumors have reported as the most common sites of solid tumors (2). In general, one of the risk factors for skin cancer is a history of sun exposure. Furthermore, radiation before HSCT and chronic grafted...
versus-host disease (GVHD) are also reported as repeatedly identified risk factors for secondary solid tumors after allo-HSCT. Given the above, secondary solid tumors are considered multifactorial. Reports of skin tumors after allo-HSCT are limited (2-5), so the clinical features and outcomes remain unclear.

We herein report a case of skin cancer in a patient with long-term voriconazole (VRCZ) administration and repeated allo-HSCT.

**Case Report**

A 47-year-old man developed AML (M2) with mixed-lineage leukemia (MLL) rearrangement in January 2009 (Figure A). After achieving his first complete remission (CR) by induction therapy and post-remission therapy, we performed allo-HSCT with the conditioning regimen of busulfan (BU)/cyclophosphamide (CY) plus short-term methotrexate (MTX) and cyclosporin (CSP) as GVHD prophylaxis. After allo-HSCT, regimen-related toxicity (RRT) was tolerable. However, recurrence was noted in December 2010. Subsequent re-induction therapy and post-remission therapy led to second CR. In April 2011, umbilical cord blood transplantation (CBSCT) was performed under the conditioning regimen of fludarabine (FLU), BU (4), and total body irradiation (TBI) (4 Gy) with tacrolimus (FK) and mycophenolate mofetil (MMF) as GVHD prophylaxis. RRT was again tolerable, but acute GVHD developed (gut: stage 1/grade 2 and skin: stage 1/grade 1). Chronic GVHD (upper and lower extremities) was pathologically diagnosed by an evaluation of a skin specimen from the upper extremities in 2011. The patient was treated with prednisolone (PSL) ointment. As it is generally known that one of the risk factors for skin cancer is a history of sun exposure, the patient shaded his face and head with a hat and sunscreen when leaving the house after suffering hair loss in 2011. In July 2018, erosion and erythema due to chronic GVHD appeared scattered over his head, and ketoconazole was used externally.

In June 2019, red nodules of around 1 cm were found on the head. Cryocoagulation therapy were performed; however, despite these treatments, the red nodules and lesions on the head became exacerbated. In December 2020, the lung aspergillus infection was treated with VRCZ, and it gradually resolved. After the withdrawal of VRCZ, red nodules and lesions on the head became exacerbated. In February 2020, red nodules on the head were biopsied and resected. Although painful parts were preferentially treated, there were multiple lesions, and the boundary between tumors was unclear in places.

In June 2019, red nodules of around 1 cm were found on the head. Cryocoagulation therapy were performed; however, despite these treatments, the red nodules and lesions on the head became exacerbated. In December 2020, the lung aspergillus infection was treated with VRCZ, and it gradually resolved. After the withdrawal of VRCZ, red nodules and lesions on the head became exacerbated. In February 2020, red nodules on the head were biopsied and resected. Although painful parts were preferentially treated, there were multiple lesions, and the boundary between tumors was unclear in places.

In April 2011, umbilical cord blood transplantation (CBSCT) was performed under the conditioning regimen of fludarabine (FLU), BU (4), and total body irradiation (TBI) (4 Gy) with tacrolimus (FK) and mycophenolate mofetil (MMF) as GVHD prophylaxis. RRT was again tolerable, but acute GVHD developed (gut: stage 1/grade 2 and skin: stage 1/grade 1). Chronic GVHD (upper and lower extremities) was pathologically diagnosed by an evaluation of a skin specimen from the upper extremities in 2011. The patient was treated with prednisolone (PSL) ointment. As it is generally known that one of the risk factors for skin cancer is a history of sun exposure, the patient shaded his face and head with a hat and sunscreen when leaving the house after suffering hair loss in 2011. In July 2018, erosion and erythema due to chronic GVHD appeared scattered over his head, and ketoconazole was used externally.

We present below the clinical course of the skin, including alopecia totalis, seborrheic keratosis, dysplasia, and multiple skin tumors [squamous cell carcinoma (SCC)] on the head (Figure B).

In 2011, after the second allo-HSCT, the patient developed alopecia totalis. In 2011, the subsequent development of chronic GVHD (skin) on the upper and lower extremities was also treated with PSL ointment. In July 2018, erosion and erythema due to chronic GVHD appeared scattered over his head, and ketoconazole was used externally.

In June 2019, red nodules of around 1 cm were found on the head. Cryocoagulation therapy were performed; however, despite these treatments, the red nodules and lesions on the head became exacerbated. In February 2020, red nodules on the head were biopsied and resected. Although painful parts were preferentially treated, there were multiple lesions, and the boundary between tumors was unclear in places.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.

In September 2020, the patient consulted Miyazaki University Hospital for skin lesion and withdrawal of VRCZ. In September 2020, VRCZ was changed into ITCZ. In December 2020, skin condition had gradually resolved after the withdrawal of VRCZ with skin maceration and radiation, with no progression of skin tumors noted.
Table. Previous Reports of Secondary Skin Tumor after Allo-HSCT.

| References | Skin cancers | Underlying disease | Allo-HSCT | Administration of VRCZ | The development of secondary skin tumors after allo-HSCT |
|------------|--------------|---------------------|-----------|-----------------------|---------------------------------------------------------|
| (2)        | 13 cases     | Not described       | +         | Not described         | 1.7% at 10 years                                         |
| (3)        | 6 cases      | Not described       | +         | Not described         | 2.4% at 10 years                                         |
| (4)        | 1 case (65, male) | MDS         | +         | +                     | 6.5 years                                               |
| (5)        | 1 case (36, female) | Not described | +         | -                     | 2.5 years, 3 years                                      |
| Our present case | 1 case (47, male) | AML    | +         | +                     | 11 years                                                |

MDS: myelodysplastic syndrome, AML: acute myeloid leukemia, Allo-HSCT: allogeneic-hematopoietic stem cell transplantation, VRCZ: voriconazole

chronic GVHD (extremities) for over seven years before the development of skin manifestations (head) in 2018, which led to the diagnosis of SCC the following year (2019). Of note, this clinical course involved a rather irregular pattern of skin chronic GVHD manifestations after allogeneic HSCT. Thus, in this situation, various effects, including the involvement of the administered drugs, needed to be considered. Notably, based on previous reports of secondary skin tumors after allo-HSCT (2-5), the case was suspected of being associated with the long-term administration of VRCZ for deep lung mycosis and pulmonary aspergillosis (over five years) and SCC. Thus, in our case, VRCZ was changed into ITCZ in September 2020. In December 2020, the skin condition had gradually resolved after the withdrawal of VRCZ with skin resection and radiation, with no progression of skin tumors noted.

In clinical practice, the concentration of VRCZ in peripheral blood may be useful to adjust the appropriate dose of VRCZ for deep lung mycosis and pulmonary aspergillosis. However, in our case, we did not measure the blood concentration of VRCZ. Thus, the concentration of VRCZ may need to be monitored in patients after allo-HSCT.

Discussion

We described a patient who developed alopecia totalis, seborrheic keratosis, dysplasia, and multiple SCCs over the long-term administration (five years) of VRCZ after repeated allo-HSCT for AML. Our case and previous reports (2-5) suggest the clinical impact of VRCZ on the risk of skin cancer in addition to allo-HSCT and chronic GVHD.

Regarding secondary malignancies after allo-HSCT, Atsuta et al. reported that risk factors for secondary malignancy after allo-HSCT included very low or very high age (under 10 years old and elderly populations), chronic GVHD, and irradiation (2). However, other risk factors for secondary malignancy after allo-HSCT have been unclear. In allo-HSCT patients, fungal infection is a lethal complication treated with anti-fungal agents, including VRCZ or ITCZ (2). In 2019, Tang et al. reported a meta-analysis of 8 studies including 3710 cases of lung transplantation and allo-HSCT, revealing the onset of SCC in 405 cases (10). Of note, the authors also suggested that the longer-term use of VRCZ (≥180 days) might increase the risk of SCC (10).

Regarding previous reports and the literature concerning secondary malignancies after allo-HSCT (2-9), 22 cases of skin tumors after allo-HSCT have been reported (Table) (2-5). Among those 22 cases, 2 were administered VRCZ during the development of secondary skin cancer after allo-HSCT. A 65-year-old man with MDS after allo-HSCT being treated with VRCZ developed SCC 6.5 years after allo-HSCT (4), and a 36-year-old woman similarly developed SCC 2.5 and 3 years after allow-HSCT (5).

Our patient, consistent with the above previous reports, had a history of repeated allo-HSCT and a history of oral administration of VRCZ for five years. VRCZ withdrawal and subsequent skin resection and radiation prevented the further onset and development of actinic keratosis and SCC. These findings also resulted in a therapeutic diagnosis and supported a close relationship between VRCZ and SCC. Consequently, our case and previous reports (2-9) suggest clinical risk factors of VRCZ for skin cancers in addition to allo-HSCT and chronic GVHD. The phototoxicity induced by VRCZ is suspected to be related to seborrheic keratosis, dysplasia, and multiple skin tumors (SCC) on the head during long-term administration (10).

In conclusion, our case suggests that long-term administration of VRCZ may be closely related to carcinogenesis of the skin in patients with a history of allo-HSCT and chronic GVHD.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We thank the medical staff, including the nurses, laboratory technicians, pharmacists, physical therapists, mental therapists, psychiatrists, and nutritionists, for their excellent care of the patients treated with allo-HSCT in our institution.

Noriaki Kawano, Shunou Nakamura, Kousuke Mochida contributed equally to this work.
References

1. Ago H. Advances and perspective in allogeneic hematopoietic cell transplantation for elderly patients. J Hematop Cell Transpl 7: 73-81, 2018 [in Japanese].
2. Atsuta Y, Suzuki R, Yamashita T, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol 25: 435-441, 2014.
3. Yokota A, Ozawa S, Masanori T, et al. Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant 47: 95-100, 2012.
4. Ng W, Takahashi A, Muto Y, Yamazaki N. High-risk cutaneous squamous cell carcinoma in a Japanese allogeneic bone marrow transplant recipient on long-term voriconazole. J Dermatol 44: 1152-1155, 2017.
5. M Furukawa, T Hamada, H Shibata, et al. Keratoacanthoma ensuing from bone marrow transplantation for chronic myeloid leukemia. 38: 83-88, 1992.
6. Au WY, Chan EC, Pang A, et al. Nonhematologic malignancies after allogeneic hematopoietic stem cell transplantation: incidence and molecular monitoring. Bone Marrow Transpl 34: 981-985, 2004.
7. Shimada K, Yokozawa T, Atsuta Y, et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors, and prognosis. Bone Marrow Transpl 36: 115-121, 2005.
8. Chen MH, Chang PM, Li WY, et al. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan. Bone Marrow Transpl 46: 567-572, 2011.
9. Munakata W, Sawada T, Kobayashi T, et al. Mortality and medical morbidity beyond 2 years after allogeneic hematopoietic stem cell transplantation: experience at a single institution. Int J Hematol 93: 517-522, 2011.
10. Tang H, Shi W, Song Y, Han J, Tang H, et al. Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: a systematic review and meta-analysis. J Am Acad Dermatol 80: 500-507, 2019.

© 2022 The Japanese Society of Internal Medicine
Intern Med 61: 2771-2774, 2022